Granted Patent
B2
US 11,382,955 · App. 17/526,929 · Granted Jul 12, 2022
Long-acting VEGF inhibitors for intraocular neovascularization
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.
Claims (1)
1. A purified anti-VEGF agent comprising amino acid residues 27 to 459 of SEQ ID NO: 3.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 14, 2022
From: FERRARA, NAPOLEONE
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 059599/0040 →
Continuity (3)
Continuation
PCTUS2020061519
· Nov 20, 2020
Provisional Application
62939756
· Nov 25, 2019